← All trials
NCT02057445
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2014
- Primary completion
- Dec 1, 2016
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- New York Medical CollegeLead sponsor
- New York Medical CollegeOverall official - principal investigator
- Children's National Medical CenterOverall official - principal investigator
- New York Medical CollegeReponsible party - principal investigator
- University of MichiganCollaborator
- University of UtahCollaborator
- Ohio UniversityCollaborator
- Johns Hopkins UniversityCollaborator
- University of Texas at HoustonCollaborator
- Children's National Medical CenterCollaborator
- Baylor UniversityCollaborator
- City of Hope National Medical CenterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.